New study analyzes cost effectiveness of smoked cannabis to treat chronic neuropathic pain

New study analyzes cost effectiveness of smoked cannabis to treat chronic neuropathic pain
Credit: Mary Ann Liebert, Inc., publishers

Smoked cannabis as an adjunctive second-line therapy to treat chronic peripheral neuropathy can be both effective and cost-effective. The results of a new study simulating its use in one million patients are published in Cannabis and Cannabinoid Research.

In the article entitled "A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain," David Grelotti, MD, University of California San Diego (La Jolla) and coauthors from UCSD, University of California Center for Medicinal Cannabis Research (San Diego), and Columbia University (New York, NY) created a computer simulation to compare the cost of usual first-, second-, and third-line care with those supplemented with smoked cannabis. They modeled efficacy and based on clinical trial and other existing study data, and derived cannabis cost from retail market pricing.

"With the continuing unabated, it is essential to understand whether cannabis might offer a safe, effective, and economically sound approach to pain management. This article offers new data that will help evaluate this possibility," says Editor-in-Chief Daniele Piomelli, Ph.D., PharmD, University of California-Irvine, School of Medicine.

Research reported in this publication was supported by the National Institutes of Health under Award Number 1TL1TR001443. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


Explore further

Future of legalized cannabis focus of expert panel discussion in cannabis journal

More information: Griffin A. Tyree et al, A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain, Cannabis and Cannabinoid Research (2019). DOI: 10.1089/can.2018.0027
Citation: New study analyzes cost effectiveness of smoked cannabis to treat chronic neuropathic pain (2019, January 29) retrieved 20 May 2022 from https://medicalxpress.com/news/2019-01-effectiveness-cannabis-chronic-neuropathic-pain.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors